Global phase 2 data in TNBC look similar to earlier results in China.
ApexOnco Front Page
Recent articles
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
First data with Astra’s torvutatug samrotecan come as Lilly unveils its first folate pivotal trial.
The Maestra-2 trial will test INCB123667 in platinum-resistant ovarian cancer.
The ESMO regular abstract lift reveals first human datasets for several projects.
Data with the T-cell engager ASP2138 look lukewarm, but could improve with combos.
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
